ADMP - アダミス・ファ―マス―ティカルズ (Adamis Pharmaceuticals Corporation) アダミス・ファ―マス―ティカルズ

 ADMPのチャート


 ADMPの企業情報

symbol ADMP
会社名 Adamis Pharmaceuticals Corp. (アダミス・ファ―マス―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company''s product portfolio includes specialty pharmaceutical products such as Epinephrine pre-filled syringe (PFS) APC-5000 dry powder inhaler (DPI) APC-1000 and APC-2000 and biotechnology products such as TeloB-VAX (vaccine) APC-100 APC-200 and APC-300. The Company''s lead product candidate the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe or the Epinephrine PFS is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.   アダミス・ファ―マス―ティカルズは米国の医薬品会社。アナフィラキシ―(急性の全身過敏症)、喘息、慢性閉塞性肺疾患、アレルギ―性鼻炎治療のネピネフリン自己注射剤、ドライパウダ―吸入器、吸入ステロイド薬の治験を行う。また、前立腺がんのテロメラ―ゼ阻害剤を治験中。本社はカリフォルニア州サンディエゴ。   
本社所在地 11682 El Camino Real Suite 300 San Diego CA 92130 USA
代表者氏名 Richard C. Williams リチャード・C・ウィリアムズ
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-997-2400
設立年月日 32660
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 126人
url www.adamispharmaceuticals.com
nasdaq_url https://www.nasdaq.com/symbol/admp
adr_tso
EBITDA EBITDA(百万ドル) -28.29893
終値(lastsale) 3.09
時価総額(marketcap) 146130296.22
時価総額 時価総額(百万ドル) 144.23860
売上高 売上高(百万ドル) 13.32986
企業価値(EV) 企業価値(EV)(百万ドル) 145.65953
当期純利益 当期純利益(百万ドル) -22.70772
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Adamis Pharmaceuticals Corp revenues increased 4% to $7.1M. Net loss increased 61% to $17.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from $2.7M to $7.1M (expense) Selling general_administrative expense increase of 14% to $12.8M (expense).

 ADMPのテクニカル分析


 ADMPのニュース

   $762.51 Million Growth in Epinephrine Autoinjector Market During 2020-2024 | Featuring Adamis Pharmaceuticals Corp. and ALK-Abello AS Among Others | Technavio  2021/02/04 13:05:00 Business Wire
LONDON--(BUSINESS WIRE)-- #GlobalEpinephrineAutoinjectorMarket--The Epinephrine Autoinjector Market will grow by USD 762.51 mn during 2020-2024
   Why Novavax, Adamis Pharma And More Are Moving Today  2021/01/29 17:07:23 Benzinga
Adamis Pharmaceuticals (NASDAQ: ADMP ) shares … Full story available on Benzinga.com
   ADMP Stock: Adamis Is Climbing on SYMJEPI News - CNA Finance  2021/01/22 13:12:49 CNA Finance
ADMP stock is screaming for the top, squeezing the shorts after announcing SYMJEPI savings for Walgreens Prescription Savings Club members.
   Adamis’ COVID-19 Treatment Has Potential, but the Stock Is Still Not a Buy: Analyst  2021/01/21 23:39:17 Yahoo Finance
2020 introduced the term “coronavirus stocks.” These are the companies working on solutions to fend off the Covid-19 global pandemic. As a result, several of the names involved in the hunt for treatments and vaccines accrued incredible gains throughout the year. With 2 vaccines already granted EUAs, and more on the way, it’s doubtful the same levels of enthusiasm could be attained for these stocks in 2021. Hold that thought, say investors of Adamis Pharma (ADMP). Shares are already up by a massive 160% this month, 78% of which were amassed in Wednesday’s session. The surge came after the company announced it has submitted an Investigational New Drug (IND) to the FDA for the use of Tempol as a treatment for COVID-19. Last June, Adamis licensed Tempol from Matrix Biomed, and in pre-clinical studies, the treatment has displayed strong anti-inflammatory, anticoagulant, and antioxidant abilities. In animal models, Tempol has exhibited the ability to lower proinflammatory cytokines (cytokine storm) and it has also shown it can decrease the genes correlated to hypoxia.
   Adamis (ADMP) Submits Tempol IND for COVID-19, Shares Soar  2021/01/21 18:27:06 Yahoo Finance
Adamis (ADMP) submits an investigational new drug (IND) to the FDA for the investigational use of Tempol for the treatment of COVID-19.
   ADMP Stock: Adamis Is Climbing on SYMJEPI News - CNA Finance  2021/01/22 13:12:49 CNA Finance
ADMP stock is screaming for the top, squeezing the shorts after announcing SYMJEPI savings for Walgreens Prescription Savings Club members.
   Adamis’ COVID-19 Treatment Has Potential, but the Stock Is Still Not a Buy: Analyst  2021/01/21 23:39:17 Yahoo Finance
2020 introduced the term “coronavirus stocks.” These are the companies working on solutions to fend off the Covid-19 global pandemic. As a result, several of the names involved in the hunt for treatments and vaccines accrued incredible gains throughout the year. With 2 vaccines already granted EUAs, and more on the way, it’s doubtful the same levels of enthusiasm could be attained for these stocks in 2021. Hold that thought, say investors of Adamis Pharma (ADMP). Shares are already up by a massive 160% this month, 78% of which were amassed in Wednesday’s session. The surge came after the company announced it has submitted an Investigational New Drug (IND) to the FDA for the use of Tempol as a treatment for COVID-19. Last June, Adamis licensed Tempol from Matrix Biomed, and in pre-clinical studies, the treatment has displayed strong anti-inflammatory, anticoagulant, and antioxidant abilities. In animal models, Tempol has exhibited the ability to lower proinflammatory cytokines (cytokine storm) and it has also shown it can decrease the genes correlated to hypoxia.
   Adamis (ADMP) Submits Tempol IND for COVID-19, Shares Soar  2021/01/21 18:27:06 Yahoo Finance
Adamis (ADMP) submits an investigational new drug (IND) to the FDA for the investigational use of Tempol for the treatment of COVID-19.
   The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping - Stocks News Feed  2021/01/21 13:05:24 Stocks News Feed
Here’s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20) 10X Genomics Inc (NASDAQ: TXG) ABIOMED, Inc. (NASDAQ: ABMD) Aclaris Therapeutics Inc (NASDAQ: ACRS) Adamis Pharmaceuticals Corp(NASDAQ: ADMP) (announced IND submission of Tempol for COVID-19 treatment) Akari Therapeutics PLC (NASDAQ: AKTX)… Read More »The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
   Gold prices sees small move from falling momentum in U.S. labor market following disappointing ADMP employment report  2020/12/02 13:18:00 KITCO
(Kitco News) - The U.S. labor market struggled to find momentum as fewer workers found jobs in November, according private payrolls processor ADP.
   Gold prices sees small move from falling momentum in U.S. labor market following disappointing ADMP employment report  2020/12/02 13:18:00 KITCO
(Kitco News) - The U.S. labor market struggled to find momentum as fewer workers found jobs in November, according private payrolls processor ADP.
   Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates  2020/11/28 18:08:21 Benzinga
The U.S. Food and Drug Administration's approval machinery churned out a lot of disappointments in November. Most of the negative verdicts were tied to difficulties the agency has had in inspecting facilities where investigational drugs are being manufactured, amid COVID-19-related restrictions. Supernus Pharmaceuticals Inc (NASDAQ: SUPN ), Alkermes Plc (NASDAQ: ALKS ), Adamis Pharmaceuticals Corp (NASDAQ: ADMP ), Bristol-Myers Squibb Co (NYSE: BMY ), Liquidia Technologies Inc (NASDAQ: LQDA ) and Revance Therapeutics Inc (NASDAQ: RVNC ) were among the companies that either received complete response letters (which indicate that the application is not ready for approval) or saw the review periods extended. Notable among the approvals issued during the month were Eiger Biopharmaceuticals Inc 's (NASDAQ: EIGR ) progeria treatment Zokinvy and Sanofi SA's (NASDAQ: SNY ) sutimlimab for treating hemolysis in adult patients with cold agglutinin disease. Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) was fortunate to get the FDA nod for its Oxlumo drug to treat primary hyperoxaluria type 1, ahead of the Dec. 3 PDUFA date.
   Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHI  2020/11/16 11:45:00 GlobeNewswire
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that after the close of…
   Adamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update  2020/11/09 21:30:00 GlobeNewswire
SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter…
   Adamis Pharmaceuticals (NASDAQ:ADMP) Trading 6.4% Higher  2020/10/21 17:58:53 US Banking News
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) traded up 6.4% during mid-day trading on Wednesday . The company traded as high as $0.86 and last traded at $0.86. 2,436,857 shares traded hands during mid-day trading, a decline of 24% from the average session volume of 3,210,064 shares. The stock had previously closed at $0.81. A number of analysts […]

 関連キーワード  (医薬品 米国株 アダミス・ファ―マス―ティカルズ ADMP Adamis Pharmaceuticals Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)